Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix

Modern Pathology

Volumn 18, Issue 1, 2005, Pages 97-104

  Dumoff, Kimberly L ^a   Chu, Christina ^a   Xu, Xiaowei ^a   Pasha, Theresa ^a   Zhang, Paul J ^a   Acs, Geza ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cervix carcinoma; D2 40 antibody; Lymph node metastasis; Lymphatic invasion; M2A antigen

Indexed keywords

M2A ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D2 40; ONCOFETAL ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; ENDOTHELIUM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR EMBOLISM; UTERINE CERVIX CARCINOMA;

ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 12344304597     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800269     Document Type: Article

References (33)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18.
2. Abulafia O, Triest WE, Sherer DM. Angiogenesis in malignancies of the female genital tract. Gynecol Oncol 1999;72:220-231.
3. Bremer GL, Tiebosch AT, van der Putten HW, et al. Tumor angiogenesis: an independent prognostic parameter in cervical cancer. Am J Obstet Gynecol 1996;174:126-131.
4. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844.
5. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
6. Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990;38:352-357.
7. Creasman WT, Kohler MF. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? Gynecol Oncol 2004;92:525-529.
8. Waggoner SE. Cervical cancer. Lancet 2003;361:2217-2225.
9. Tsai CS, Lai CH, Wang CC, et al. The prognostic factors for patients with early cervical cancer treated by radical hysterectomy and postoperative radiotherapy. Gynecol Oncol 1999;75:328-333.
10. Clarijs R, Ruiter DJ, de Waal RM. Lymphangiogenesis in malignant tumours: does it occur? J Pathol 2001;193:143-146.
11. Karpanen T, Alitalo K. Lymphatic vessels as targets of tumor therapy? J Exp Med 2001;194:F37-F42.
12. Sleeman JP, Krishnan J, Kirkin V, et al. Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech 2001;55:61-69.
13. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999;80:569-578.
14. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-1257.
15. FIGO stages (announcements) - 1988 revision. Gynecol Oncol 1989;35:125-127.
16. Kurman RJ, Norris HJ, Wilkinson EJ. Tumors of the Cervix, Vagina, and Vulva. Armed Forces Institute of Pathology: Washington, DC, 1992.
17. Acs G, Lawton TJ, Rebbeck TR, et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001;115:85-98.
18. Bailey D, Baumal R, Law J, et al. Production of a monoclonal antibody specific for seminomas and dysgerminomas. Proc Natl Acad Sci USA 1986;83:5291-5295.
19. Baumal R, Bailey D, Giwercman A, et al. A novel maturation marker for human Sertoli cells. Int J Androl 1989;12:354-359.
20. Sutherland DR, Rudd CE, Greaves MF. Isolation and characterization of a human T lymphocyte-associated glycoprotein (gp40). J Immunol 1984;133:327-333.
21. Carraway KL, Hull SR. O-glycosylation pathway for mucin-type glycoproteins. Bioessays 1989;10:117-121.
22. Lesuffleur T, Zweibaum A, Real FX. Mucins in normal and neoplastic human gastrointestinal tissues. Crit Rev Oncol Hematol 1994;17:153-180.
23. Strous GJ, Dekker J. Mucin-type glycoproteins. Crit Rev Biochem Mol Biol 1992;27:57-92.
24. McNeer RR, Huang D, Fregien NL, et al. Sialomucin complex in the rat respiratory tract: a model for its role in epithelial protection. Biochem J 1998;330:737-744.
25. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995;57:607-634.
26. Carraway KL, Perez A, Idris N, et al. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive. Prog Nucleic Acid Res Mol Biol 2002;71:149-185.
27. Komatsu M, Yee L, Carraway KL. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. Cancer Res 1999;59:2229-2236.
28. Price-Schiavi SA, Jepson S, Li P, et al. Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 2002;99:783-791.
29. Klapper LN, Kirschbaum MH, Sela M, et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79.
30. Carraway KL, Ramsauer VP, Haq B, et al. Cell signaling through membrane mucins. Bioessays 2003;25:66-71.
31. Komatsu M, Jepson S, Arango ME, et al. Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene 2001;20:461-470.
32. Yamamoto M, Bharti A, Li Y, et al. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem 1997;272:12492-12494.
33. Wesseling J, van der Valk SW, Vos HL, et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995;129:255-265.